This prospective study within the general population demonstrates that SAF is significantly associated with new-onset type 2 diabetes, CVD and mortality during a median follow-up of 4 years. SAF predicted these combined outcomes independently of several conventional risk factors, including age, sex, waist circumference, the metabolic syndrome, smoking status, fasting glucose and/or HbA1c.
Both fasting glucose and HbA1c were used to define type 2 diabetes at follow-up, which may have caused overestimation of their predictive values. SAF also significantly predicted mortality alone, even after correction for all relevant risk factors, such as age, sex, waist circumference and smoking. Finally, SAF was most strongly predictive in participants aged 36 and above, probably because of the low incidence of events in the lowest age group (age ≤35 years, Table 5).
The formation and accumulation of AGEs is increased in individuals with diabetes as a result of chronic hyperglycaemia and oxidative stress [8, 33]. In the present study, SAF levels were already elevated at baseline before diagnosis of type 2 diabetes, compared with people who remained normoglycaemic. Indeed, previously we demonstrated that SAF levels were strongly correlated with presence of the metabolic syndrome, a cluster of risk factors which is associated with increased risk of type 2 diabetes [21]. This association has been confirmed in the present study. However, SAF remained an independent predictor of incident type 2 diabetes, even when adjusted for presence of the metabolic syndrome at baseline. Our analyses also revealed that SAF predicted incident type 2 diabetes when adjusted for fasting glucose and HbA1c levels, and it remained significantly associated even when adjusted for a large number of variables, including glycaemic measures, age, waist circumference, BP, triacylglycerol and eGFR.
Several earlier cross-sectional studies have assessed whether SAF is able to detect undiagnosed type 2 diabetes. Based on various receiver operating characteristic curves, skin fluorescence measured with the Scout DS device had higher sensitivity and specificity compared with fasting plasma glucose and HbA1c in the detection of individuals with undiagnosed abnormal glucose tolerance [34]. However, these analyses were not corrected for important factors such as age, waist circumference, glucose level and smoking status. Another study compared an SAF decision model, based on age percentiles, BMI and family history, with the Finnish Diabetes Risk Score (FINDRISC) questionnaire and conventional risk markers, including fasting plasma glucose and HbA1c, for the detection of prevalent impaired glucose tolerance and diabetes [35]. Analyses in a subgroup of individuals, classified a priori as intermediate risk, showed that the SAF-based decision model had a higher sensitivity and specificity compared with fasting plasma glucose alone and the FINDRISC questionnaire, and had a performance equal to HbA1c. Finally, our group recently demonstrated in the same Lifelines cohort that measurement of SAF is of additional value to the FINDRISC for detecting current undiagnosed diabetes [36]. Reclassification analysis showed that SAF reclassified 8–15% of the total population into more accurate risk categories.
In the current study, SAF was also significantly associated with a threefold increased risk of incident CVD. This association remained significant after adjustment for age and sex, as well as the metabolic syndrome, which includes presence of elevated waist circumference, elevated BP, low HDL-cholesterol and triacylglycerol, all well-known risk factors for CVD [37, 38]. SAF remained significantly associated even after adjustment for important CVD risk factors such as actual BP levels, total cholesterol and current smoking. It has been demonstrated that tobacco smoking is a strong risk factor for a wide range of CVDs [39, 40]. Tobacco smoke is also an exogenous source of AGEs and increases oxidative stress [41,42,43]; both active and passive smoking significantly increase SAF [19, 20, 44]. This also suggests that the association between smoking status and risk of CVD may, in part, be explained by increased accumulation of AGEs as a result of tobacco smoking. Also, it should be noted that baseline SAF scores were the highest in individuals who developed both type 2 diabetes and CVD (Fig. 2). Although this is a small subgroup of only 55 participants, it supports the power of SAF for predicting very-high-risk individuals.
The most striking finding was that SAF was associated with a fivefold increased mortality risk in our univariate analysis. This association remained highly significant even after correcting for several confounding factors, including those described in the most extensive fifth model (Table 4). The results in Table 5 showed high ORs that are highly significant for all age groups. As this is the first study that evaluated the effect of SAF in the general non-diabetic population, we have no other study results for comparison. Although several cross-sectional studies have demonstrated the association between SAF and macro- and microvascular complications of type 2 diabetes, prospective studies regarding the predictive value of SAF are scarce and limited to selected patient populations [19, 23, 24]. SAF has been shown to be a prognostic factor for cardiac mortality in individuals with diabetes [45] and in those receiving haemodialysis [46,47,48]. De Vos et al have shown that SAF predicts all-cause mortality and major adverse cardiovascular events in participants with peripheral artery disease after 5 years of follow-up [25]. Moreover, in the same patient population, they found that SAF predicted lower limb amputation independently of diabetes status and disease severity after 6 years of follow-up [26]. Addition of SAF to the Fontaine classification, a method to assess severity of peripheral artery disease, improved the prediction of amputation significantly.
Both previous and present findings support the clinical utility of SAF as a first screening method for type 2 diabetes, CVD and mortality. Other risk indicators, such as presence of the metabolic syndrome, require more extensive measurements, including a fasting blood sample to measure glucose, HDL-cholesterol and triacylglycerol, but HbA1c solves the need for measuring fasting glucose. The quick, non-invasive measurement of SAF may even allow use in non-medical settings or public locations such as supermarkets, pharmacies or drug stores as a first estimate of risk. The AGE reader in the present study may be used to calculate SAF percentiles using measurements in healthy participants, based on the data from Koetsier et al [20]. The present version of the device can account for both age and sex, but BMI and smoking status might also be accounted for, to produce a more balanced interpretation of the SAF value.
Strengths and limitations
We have presented data from a prospective population-based study that included almost 73,000 participants within a broad range of age and cardiovascular risk. This is the first prospective study to examine SAF as a predictor for type 2 diabetes, CVD and mortality in the general population. Although Lifelines extensively collected information on medication use at baseline, unfortunately no data were available on the use of new medications or changes in medications, as this information was not included in the follow-up questionnaires. Medication use, in particular oral blood-glucose-lowering agents and/or insulin, can validate self-reported diagnosis of type 2 diabetes, or even ascertain the presence of diabetes when a participant does not report diabetes correctly in the questionnaire. Also, data regarding the exact time of diabetes diagnosis and CVD events were not collected. As a consequence, we were not able to perform survival analyses for both diseases. We do not have follow-up blood glucose or HbA1c measurements for 16,720 participants. This may underestimate the incidence of type 2 diabetes, and could alter the effects described.
As the study has been performed in people of Western European descent, the results may not be generalisable to other populations.
Finally, future studies need to incorporate the specific cause of death in order to further refine the predictive power of SAF.
Conclusions
This is the first prospective study in the general population to show the predictive value of SAF for incident type 2 diabetes, CVD and mortality. SAF significantly predicted the risk of these outcomes independently of several conventional risk factors. A longer follow-up of Lifelines participants will allow further validation and will expand the present findings.